<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01788618</url>
  </required_header>
  <id_info>
    <org_study_id>COG REDUC</org_study_id>
    <nct_id>NCT01788618</nct_id>
  </id_info>
  <brief_title>Cancer and Disorders of Cognitive Functions and Quality of Life: &quot;Cognitive Rehabilitation in Patients Suffering From Cancer and Treated With Chemotherapy&quot;</brief_title>
  <official_title>Cancer and Disorders of Cognitive Functions and Quality of Life: &quot;Cognitive Rehabilitation in Patients Suffering From Cancer and Treated With Chemotherapy&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study aims to measure the impact of cognitive rehabilitation workshops on the development&#xD;
      of cognitive functions and quality of life of patients expressing a cognitive complaint&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of our study was to evaluate, in patients treated for cancer expressing&#xD;
      the cognitive complaint during or after treatment, interest workshops on improving cognitive&#xD;
      rehabilitation felt their cognitive functions and their quality of life.&#xD;
&#xD;
      The primary endpoint was the proportion of patients showing an improvement in the score of&#xD;
      perceived deficiencies (score ranging from 0 to 72) of the FACT-Cog after treatment. The&#xD;
      FACT-Cog is a self-administered questionnaire assessing the patients felt their cognitive&#xD;
      difficulties (memory, attention, concentration) and the impact of these difficulties on their&#xD;
      quality of life. The improvement is defined as an increase of 7 points &gt;= cognitive score won&#xD;
      by the (a) patient (e) after the treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients showing an improvement in the score of perceived deficiencies (score ranging from 0 to 72) of the FACT-Cog after care</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Evaluate, in patients treated for cancer expressing a cognitive complaint during or after the treatment, the interest workshops on improving cognitive rehabilitation felt their cognitive function and quality of life.&#xD;
Autoquestionnary FACT COG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the relationship between cognitive impairment and the parameters of the quality of life</measure>
    <time_frame>Baseline and month 3</time_frame>
    <description>Cognitive assessment:&#xD;
MMS, Test de Grober et Buschke, mémoire des chiffres (WAIS IV), séquence lettres-chiffres (WAIS IV), arithmétique (WAIS IV), Trail Making Test, Fluence verbale, D2, Code (WAIS IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the relationships between goals disorders (measured by neuropsychological tests) and the patients felt</measure>
    <time_frame>Baseline and month 3</time_frame>
    <description>Cognitive assessment:&#xD;
MMS, Test de Grober et Buschke, mémoire des chiffres (WAIS IV), séquence lettres-chiffres (WAIS IV), arithmétique (WAIS IV), Trail Making Test, Fluence verbale, D2, Code (WAIS IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of different types of interest support the evolution of objective and subjective cognitive performance of patients</measure>
    <time_frame>Baseline and month 3</time_frame>
    <description>Cognitive assesment:&#xD;
MMS, Test de Grober et Buschke, mémoire des chiffres (WAIS IV), séquence lettres-chiffres (WAIS IV), arithmétique (WAIS IV), Trail Making Test, Fluence verbale, D2, Code (WAIS IV)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cognitive exams at T0 and T3. Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The control group 1 (Homework)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cognitive exams at T0 and T3. These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group 2 ( telephone follow)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cognitive exams at T0 and T3. These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive exams</intervention_name>
    <description>Psychopathological assessment (T0 and T3):&#xD;
Scale of Spielberger&#xD;
The self-administered questionnaire CES-D&#xD;
Cognitive assessment(T0 and T3):&#xD;
- MMS, Grober and Buschke test, memory for numbers (WAIS IV) sequence of numbers and letters (WAIS IV), arithmetic (WAIS IV), Trail Making Test, verbal Fluence, D2, Code (WAIS IV)&#xD;
Quality of Life: FACT-G and FACT-An Fatigue Module (T0 and T3):&#xD;
Self-assessment FACT-COG (T0,every months until T3)</description>
    <arm_group_label>Control group 2 ( telephone follow)</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>The control group 1 (Homework)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standardized cognitive rehabilitation</intervention_name>
    <description>Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardized home exercise</intervention_name>
    <description>These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog</description>
    <arm_group_label>The control group 1 (Homework)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Follow up by phone</intervention_name>
    <description>These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog</description>
    <arm_group_label>Control group 2 ( telephone follow)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 years&#xD;
&#xD;
          -  Solid tumor or haematological&#xD;
&#xD;
          -  Chemotherapy and / or targeted therapy in the adjuvant or metastatic&#xD;
&#xD;
          -  Sequential processing&#xD;
&#xD;
          -  Subjective cognitive complaints during or after treatment assessed by four items of&#xD;
             the FACT-COG (impact on quality of life). Score ≥ 4/16 questions Q35, Q37, Q38 and Q41&#xD;
             FACT COG - Patient in remission or pause therapeutic&#xD;
&#xD;
          -  Subjective between 1 month and 5 years after the end of chemotherapy and / or targeted&#xD;
             therapy cognitive complaints (ongoing treatment with Herceptin is not a non-inclusion&#xD;
             criteria)&#xD;
&#xD;
          -  Lack of personality disorders and / or psychiatric disorder scalable&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Lack of primary brain tumor&#xD;
&#xD;
          -  Lack of analgesic treatment with opioids or Class 3&#xD;
&#xD;
          -  Having signed informed consent to participate in the study&#xD;
&#xD;
          -  Mastery of the French language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary cancer of the central nervous system or brain metastases&#xD;
&#xD;
          -  Pathology malignant hematologic&#xD;
&#xD;
          -  Disorders of higher functions documented&#xD;
&#xD;
          -  Pathology psychiatric scalable&#xD;
&#xD;
          -  Use documented drug&#xD;
&#xD;
          -  Cancer treated in childhood&#xD;
&#xD;
          -  Patient or opioids analgesics in Class 3&#xD;
&#xD;
          -  Consumption of alcohol&#xD;
&#xD;
          -  Patient unable to respond to cognitive tests and cognitive rehabilitation&#xD;
&#xD;
          -  Refusal to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence JOLY-LOBBEDEZ, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>46038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>February 8, 2013</study_first_submitted>
  <study_first_submitted_qc>February 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2013</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognitive functions</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

